Immune Checkpoint Programmed Cell Death Protein-1 (PD-1) Expression on Bone Marrow T Cell Subsets in Patients With Plasma Cell Myeloma
BACKGROUND: Plasma cell myeloma (PCM) is caused by immune dysregulation. We evaluated the expression of immune checkpoint programmed cell death protein-1 (PD-1) on T cell subsets in PCM patients according to disease course and cytogenetic abnormalities. This study aimed to find a target group suitable for therapeutic use of PD-1 blockade in PCM.
METHODS: A total of 188 bone marrow (BM) samples from 166 PCM patients and 32 controls were prospectively collected between May 2016 and May 2017. PD-1 expression on BM T cell subsets was measured using flow cytometry.
RESULTS: At diagnosis, the median PD-1 expression on CD4+ T cells was 24.6%, which did not significantly differ from that in controls. After stem cell transplantation, PD-1 expression on CD4+ T cells was higher than that at diagnosis (P<0.001), regardless of residual disease. PD-1 expression on CD4+ T cells in patients with residual disease after chemotherapy was significantly higher than that at diagnosis (P=0.001) and after complete remission following chemotherapy (P=0.044). PD-1 expression on CD8+ T cells was higher in PCM patients with cytogenetic abnormalities, including monosomy 13, 1q gain, complex karyotype, and hypodiploidy.
CONCLUSIONS: PD-1 blockade might have therapeutic potential in refractory PCM patients after chemotherapy, especially in those with high- or intermediate-risk cytogenetic abnormalities.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
Annals of laboratory medicine - 41(2021), 3 vom: 01. Mai, Seite 259-267 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lee, Min Young [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Apoptosis Regulatory Proteins |
|---|
| Anmerkungen: |
Date Completed 09.09.2021 Date Revised 18.04.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.3343/alm.2021.41.3.259 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM318690683 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM318690683 | ||
| 003 | DE-627 | ||
| 005 | 20231226202318.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3343/alm.2021.41.3.259 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1062.xml |
| 035 | |a (DE-627)NLM318690683 | ||
| 035 | |a (NLM)33303710 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lee, Min Young |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immune Checkpoint Programmed Cell Death Protein-1 (PD-1) Expression on Bone Marrow T Cell Subsets in Patients With Plasma Cell Myeloma |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.09.2021 | ||
| 500 | |a Date Revised 18.04.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Plasma cell myeloma (PCM) is caused by immune dysregulation. We evaluated the expression of immune checkpoint programmed cell death protein-1 (PD-1) on T cell subsets in PCM patients according to disease course and cytogenetic abnormalities. This study aimed to find a target group suitable for therapeutic use of PD-1 blockade in PCM | ||
| 520 | |a METHODS: A total of 188 bone marrow (BM) samples from 166 PCM patients and 32 controls were prospectively collected between May 2016 and May 2017. PD-1 expression on BM T cell subsets was measured using flow cytometry | ||
| 520 | |a RESULTS: At diagnosis, the median PD-1 expression on CD4+ T cells was 24.6%, which did not significantly differ from that in controls. After stem cell transplantation, PD-1 expression on CD4+ T cells was higher than that at diagnosis (P<0.001), regardless of residual disease. PD-1 expression on CD4+ T cells in patients with residual disease after chemotherapy was significantly higher than that at diagnosis (P=0.001) and after complete remission following chemotherapy (P=0.044). PD-1 expression on CD8+ T cells was higher in PCM patients with cytogenetic abnormalities, including monosomy 13, 1q gain, complex karyotype, and hypodiploidy | ||
| 520 | |a CONCLUSIONS: PD-1 blockade might have therapeutic potential in refractory PCM patients after chemotherapy, especially in those with high- or intermediate-risk cytogenetic abnormalities | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Flow cytometry | |
| 650 | 4 | |a Immune checkpoint programmed cell death protein-1 (PD-1) | |
| 650 | 4 | |a Plasma cell myeloma | |
| 650 | 4 | |a T cell subset | |
| 650 | 7 | |a Apoptosis Regulatory Proteins |2 NLM | |
| 650 | 7 | |a Programmed Cell Death 1 Receptor |2 NLM | |
| 700 | 1 | |a Park, Chan-Jeoung |e verfasserin |4 aut | |
| 700 | 1 | |a Cho, Young-Uk |e verfasserin |4 aut | |
| 700 | 1 | |a You, Eunkyoung |e verfasserin |4 aut | |
| 700 | 1 | |a Jang, Seongsoo |e verfasserin |4 aut | |
| 700 | 1 | |a Seo, Eul Ju |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Jung-Hee |e verfasserin |4 aut | |
| 700 | 1 | |a Yoon, Dok Hyun |e verfasserin |4 aut | |
| 700 | 1 | |a Suh, Cheolwon |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of laboratory medicine |d 2012 |g 41(2021), 3 vom: 01. Mai, Seite 259-267 |w (DE-627)NLM215937082 |x 2234-3814 |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2021 |g number:3 |g day:01 |g month:05 |g pages:259-267 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3343/alm.2021.41.3.259 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 41 |j 2021 |e 3 |b 01 |c 05 |h 259-267 | ||